Navigation Links
BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
Date:1/7/2009

y's history," said Mr. Moch. "I believe that BME's unique technology and innovative products have tremendous commercial growth potential. Together with BME's talented employees, I look forward to accelerating the growth of the Company and broadening the use of our novel memory metal implants."

"Ken's involvement is a statement to our distributor partners that we intend to grow our business for our mutual benefit. With in-house manufacturing now on line at BME we have the capability, support and focus for new product development and the continued improvement of our product lines," said Casey Fox, PhD.

About BioMedical Enterprises, Inc.

BME designs, manufactures and markets memory metal implants used in orthopaedic reconstructive surgery and fracture management. BME's patented implant system utilizes the unique properties of the shape memory alloy nitinol to provide controlled long-term compression that enhances the body's natural healing process in an effort to achieve faster healing times and fewer complications. BME's barbed and smooth OSStaple(TM) lines of bone fusion implants, part of the OSSforce(TM) fixation system, are designed to achieve controlled long-term compression of bone fragments. BME's OSSAnchor(TM) line of soft tissue fixation implants give surgeons a simple yet powerful tool to attach soft tissue to bone.

For more information about BME and its unique products visit http://www.bme-tx.com.


'/>"/>
SOURCE BioMedical Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
2. Response Biomedical Corporation Announces Change of Executives
3. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
4. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
5. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
6. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
7. Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
8. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases
9. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
10. Interview with Dr. Elisabeth Hager, CEO of Balan Biomedical, Inc., to Air Nationally on Sky Radio
11. Response Biomedical Closes $5.1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Prime Healthcare Services to Acquire Three Hospitals from Tenet Healthcare Corporation 2Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 2Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 3Health News:Meetings with Pre-Screened Verified China Suppliers Help 14 Top Buyers, Including Brookstone and Staples, Save Time and Cut Sourcing Costs 4Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 2Health News:More girls than boys benefit from breastfeeding, Hopkins Children's research shows 3Health News:Bunk beds pose dangers to kids and adults 2Health News:Bunk beds pose dangers to kids and adults 3Health News:Large study identifies most costly adverse events in children's hospitals 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 1Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 3Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 4Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 5Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 6Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 7Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 8Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 9Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 10Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 11ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 1ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 2ULURU Inc to Present Altrazeal 28TM 29 Clinical Evidence at the American Podiatric Medical Association 28APMA 29 Annual Scientific Meeting in Toront 53161 3Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 1Regence Wins Awards for Consumer Appeal to Transform Health Care 53156 2